Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 11/20 | 0.43 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 9/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3512477 | 0.92 | ALDH1A1 (0.51) | ALDH1A1KDM4EACHEBIRC5BCHE | |
| SCHEMBL188299 | 0.84 | HTR7 (0.44) | ALDH1A1KDM4EACHEBCHE | |
| SCHEMBL7180376 | 0.82 | CYP1A2 (0.41) | ALDH1A1TDP1 | |
| SCHEMBL27852671 | 0.82 | KDM4E (0.50) | ALDH1A1KDM4ETDP1BIRC5 | |
| SCHEMBL8348135 | 0.81 | L3MBTL1 (0.38) | ALDH1A1TDP1 | |
| SCHEMBL542448 | 0.80 | KDM4E (0.40) | ALDH1A1KDM4ETDP1 | |
| SCHEMBL6200785 | 0.80 | ALDH1A1 (0.43) | ALDH1A1TDP1CHRM2 | |
| SCHEMBL11717070 | 0.80 | ALDH1A1 (0.43) | ALDH1A1TDP1CHRM2 | |
| SCHEMBL7347065 | 0.80 | L3MBTL1 (0.40) | ALDH1A1TDP1 | |
| SCHEMBL2479633 | 0.80 | HTR7 (0.53) | ALDH1A1KDM4EACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305113-A1 | Substituted Imidazopyridazines as Lipid Kinase Inhibitors | CAPRARO HANS-GEORG | 2010-12-02 | — | — | US | disclosed |
| EP-2155753-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AS PI3K LIPID KINASE INHIBITORS | Novartis Ag (CH) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008138834-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AS PI3K LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305113-A1 | Substituted Imidazopyridazines as Lipid Kinase Inhibitors | PI4KA, PIK3CA, PIK3CB | ALDH1A1 1154/4885KDM4E 898/4885TDP1 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.